Cyclophosphamide, Thalidomide, and Dexamethasone as Initial Therapy for Patients With Newly Diagnosed Multiple Myeloma in a Middle-Income Country: 7-Year Follow-Up A total of 962 cases of CML on ...
Calculating halving time of the BCR-ABL transcript after 3 months may help determine prognosis in chronic myeloid leukaemia (CML) patients undergoing first-line tyrosine kinase inhibitor (TKI) therapy ...
MSD’s acquisition of Terns Pharmaceuticals is a calculated, forward-looking manoeuvre to secure the next generation of haematology assets.
Subcutaneous omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients resistant or intolerant to two or more tyrosine kinase inhibitors (TKIs): Data from an ongoing phase II trial This is ...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for ...
Expert Rev Anticancer Ther. 2008;8(9):1387-1398. Expert Rev Anticancer Ther. 2008;8(9):1387-1398. © 2008 Expert Reviews Ltd. No writing assistance was utilized in ...
Introducing BCR-ABL as target for third program, in development for CML and Ph+ ALL; development candidate nomination expected by early 2024 CAMBRIDGE, Mass., Jan. 5, 2023 /PRNewswire/ -- Theseus ...
FOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results